Curiox Biosystems Co., Ltd (KOSDAQ:445680)
South Korea flag South Korea · Delayed Price · Currency is KRW
45,250
+2,550 (5.97%)
At close: Aug 11, 2026

Curiox Biosystems Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
5,5555,1524,5886,7887,2375,523
Revenue Growth
41.63%12.29%-32.41%-6.21%31.04%25.97%
Gross Profit
2,0862,1352,5593,8254,7333,494
Operating Income
-12,542-12,314-13,378-10,557-11,421-8,337
Net Income
-26,200-27,177-8,089-10,040-11,495-14,524
Earnings Per Share
-1563.11-1645.17-503.00-702.41-1619.76-1114.50
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
16,66417,78528,18817,9098,72219,819
Total Debt
2,5572,4508,142965.16387.2130,446
Net Cash (Debt)
14,10715,33520,04516,9448,334-10,627
Net Cash Growth
-16.43%-23.50%18.30%103.30%--
Net Cash Per Share
841.60928.331246.491185.371174.42-815.46

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-9,015-11,109-9,698-8,164-9,888-5,126
Capital Expenditures
-137.84-136.1-257.88-211.53-822.86-261.26
Free Cash Flow
-9,153-11,245-9,956-8,376-10,711-5,387
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
37.55%41.45%55.77%56.35%65.40%63.27%
Operating Margin
-225.80%-239.04%-291.61%-155.53%-157.81%-150.95%
Pretax Margin
-473.54%-530.56%-174.29%-150.43%-156.01%-266.04%
Profit Margin
-471.69%-527.55%-176.32%-147.92%-158.83%-262.98%
FCF Margin
-164.78%-218.29%-217.02%-123.39%-148.00%-97.54%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
140.15388.8265.2359.45--